Objective of the study: Clozapine is one of well-known antipsychotics which causes hematologic adverse effects, specifically neutropenia and agranulocytosis (1-3% of patients). We found a rare case of thrombocytosis and anemia after the re-administration of clozapine. Methods used: We reviewed the documents about clozapine induced hematologic adverse-effects, esp. anemia and thrombocytosis. And we summarized the case of anemia and thrombocytosis after re-start of clozapine by the result of hematologic work-up and clinical responses of it. Summary of results: Reports about blood dyscrasias like anemia and thrombocytosis after clozapine treatment has been extremely rare. In some cases, re-challenge of clozapine could lead to hematopoietic abnormality related to thrombocytopenia or thrombocytosis, which is may be a result of an immune reaction. The details of hematologic finding are shown in the graph. Conclusions reaches: This case report suggest that clinician should monitor platelet count after the re-treatment of clozapine.
PM416
Efficacy and tolerability of paliperidone palmitate long-acting injectable antipsychotic: off-label use in first-episode adolescent schizophrenic patients Daniela Petrić1, Valentino Rački2, Mirjana Graovac1, Ana Kaštelan1 
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Abstract Objective: Aim of the paper is to assess the therapeutic efficacy and tolerability of paliperidone palmitate long-acting injectable antipsychotic in first-episode adolescent schizophrenic patients. The management of patients with a first-episode of psychosis remains a challenge. Treating patients with paliperidone palmitate avoids the issue of non-compliance. Methods: The research included 18 patients aged 15 to 17 years who were diagnosed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. All patients were assessed six times over twelve months using the following clinical scales: Positive and Negative Syndrome Scale, Clinical Global Impression -Severity and Improvement Scale, Personal and Social Performance Scale. Primary safety measures included incidence of adverse events. Patients and their families have given consent for the treatment. Results: In this twelve-month analysis all patients with firstepisode psychosis achieved remission, which was significantly associated with early treatment response. There were no hospitalizations during this period. Patients demonstrated a trend towards greater improvement in function, health status and productivity. Conclusion: All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated. Earlier application of paliperidone palmitate resulted in no relapse, better reaction to therapy, achieving remission and full recovery.
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Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia The QUALIFY (QUAlity of LIfe with AbiliFY Maintena) study compared the effectiveness of aripiprazole once-monthly 400 mg (AOM 400) to paliperidone palmitate once-monthly (PP) using Heinrichs-Carpenter Quality-of-Life Scale (QLS) [1, 2] . The Readiness for Work Questionnaire (WoRQ) was an additional functional endpoint [3] . This post-hoc analysis investigates the relationship between QLS/WoRQ following treatment. Methods: QUALIFY was a 28-week, randomized, open-label, raterblinded, head-to-head study (NCT01795547) of 2 atypical longacting injectable anti-psychotics in patients (18-60 years) with schizophrenia. The primary endpoint was change from baseline to week 28 in QLS total score [1] . WoRQ-derived work readiness (Yes/No) was assessed at baseline and week 28. Irrespective of treatment, patients were categorized by work readiness at baseline and week 28 (No-to-Yes, Yes-to-Yes, or No at week 28), and changes from baseline to week 28 in QLS total, domain, and items scores were assessed with a mixed model for repeated measures. Results: QLS total score showed superior improvement with AOM 400 vs PP and more patients changed from No-to-Yes in work readiness with AOM 400 vs PP treatment (39.2% vs 17.4%) with greater odds of work readiness at week 28. Patients in the No-to-Yes group (n=41) showed least squares mean (LSM) changes in QLS total score of 14.3 ± 2.2, significantly greater than No at week 28 group (n=118; LSM change: 2.7 ± 1.4; LSM difference: 11.6 ± 2.6, 95%CI:[6.5;16.7], p<0.0001). QLS instrumental role domain scores were significantly improved in the No-to-Yes group vs No at week 28 group, with LSM improvements of ~1 point on each item. Conclusion: These results show a strong association between shifts in work readiness and improvements on QLS, particularly in QLS categories related to work functioning. The association between functional improvements in health-related quality of life and work readiness suggest that increasing patients' capacity to work is a realistic goal in the treatment of schizophrenia.
